OUTLOOK THERAPEUTICS INC - Asset Resilience Ratio

Latest as of June 2024: 0.00%

OUTLOOK THERAPEUTICS INC (OTLK) has an Asset Resilience Ratio of 0.00% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check OUTLOOK THERAPEUTICS INC (OTLK) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$1.00
Cash + Short-term Investments

Total Assets

$47.09 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how OUTLOOK THERAPEUTICS INC's Asset Resilience Ratio has changed over time. See OTLK equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down OUTLOOK THERAPEUTICS INC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of OUTLOOK THERAPEUTICS INC.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $1.00 0.0%
Total Liquid Assets $1.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: OUTLOOK THERAPEUTICS INC maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

OUTLOOK THERAPEUTICS INC Industry Peers by Asset Resilience Ratio

Compare OUTLOOK THERAPEUTICS INC's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Biotechnology -55.36%
Krystal Biotech Inc
NASDAQ:KRYS
Biotechnology 23.06%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for OUTLOOK THERAPEUTICS INC (None–None)

The table below shows the annual Asset Resilience Ratio data for OUTLOOK THERAPEUTICS INC.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
No yearly data available.
pp = percentage points

About OUTLOOK THERAPEUTICS INC

NASDAQ:OTLK USA Biotechnology
Market Cap
$121.29 Million
Market Cap Rank
#23198 Global
#4994 in USA
Share Price
$1.65
Change (1 day)
+5.10%
52-Week Range
$0.20 - $2.97
All Time High
$867.20
About

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other … Read more